Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14548162 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL80731 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL14130407 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL80732 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL13559128 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL12449334 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL18271744 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL14130644 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL12521907 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 | |
| SCHEMBL725337 | 1.00 | TRPA1 (0.43) | TRPA1TRPM8GBA1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118984825-A | Novel cooling agent and preparation containing same | 西姆莱斯股份公司 | 2024-11-19 | — | — | CN | claimed |
| EP-4268814-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE | Universidad Miguel Hernández De Elche (ES) | 2023-11-01 | — | — | EP | claimed |
| WO-2023143741-A1 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-08-03 | — | — | WO | claimed |
| EP-4103287-A1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS AND COOLING AGENTS | Symrise AG (DE) | 2022-12-21 | — | — | EP | claimed |
| WO-2022122903-A1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS AND COOLING AGENTS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| WO-2022122134-A1 | COMPOSITIONS WITH (BIO)-ALKANEDIOLS AND COOLING AGENTS | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| EP-3996506-A1 | FORMULATIONS FOR CONTROL AND REPELLENCY OF BITING ARTHROPODS | Bedoukian Research, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3996505-A1 | SYNERGISTIC FORMULATIONS FOR CONTROL AND REPELLENCY OF BITING ARTHROPODS | Bedoukian Research, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| US-20260101914-A1 | VANILLA COMPOSITION | FIRMENICH & CIE (CH) | 2026-04-16 | — | — | US | disclosed |
| EP-4723887-A1 | METHODS AND COMPOUNDS | University of Leicester (GB) | 2026-04-15 | — | — | EP | disclosed |
| US-20250344733-A1 | FLAVOR NANOEMULSIONS FOR BEVERAGE AND PERSONAL CARE APPLICATIONS | FIRMENICH SA (CH) | 2025-11-13 | — | — | US | disclosed |
| EP-4503939-A1 | FLAVOR NANOEMULSIONS FOR BEVERAGE AND PERSONAL CARE APPLICATIONS | Firmenich SA (CH) | 2025-02-12 | — | — | EP | disclosed |
| CN-119317358-A | Flavor nanoemulsions for beverage and personal care applications | 弗门尼舍有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024252135-A1 | METHODS AND COMPOUNDS | UNIVERSITY OF LEICESTER (GB) | 2024-12-12 | — | — | WO | disclosed |
| US-7396547-B2 | Antiseptic composition | CLARKE PAUL DOUGLAS | 2008-07-08 | — | — | US | disclosed |
| US-7396547-B2 | Antiseptic composition | CLARKE PAUL DOUGLAS | 2008-07-08 | — | — | US | disclosed |
| US-20070122499-A1 | ANTISEPTIC COMPOSITION | CLARKE PAUL D | 2007-05-31 | — | — | US | disclosed |
| US-20070122499-A1 | ANTISEPTIC COMPOSITION | CLARKE PAUL D | 2007-05-31 | — | — | US | disclosed |
| US-7189421-B2 | Antiseptic composition | CLARKE PAUL DOUGLAS | 2007-03-13 | — | — | US | disclosed |
| US-7189421-B2 | Antiseptic composition | CLARKE PAUL DOUGLAS | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260101914-A1 | VANILLA COMPOSITION | TAS2R19, TAS2R9, TAS2R39 | TRPA1 175/4885TRPM8 189/4885GBA1 4529/4885 |
| US-20070122499-A1 | ANTISEPTIC COMPOSITION | DPM1, CUTA, NACA | TRPA1 267/4885TRPM8 188/4885GBA1 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.